Rani Therapeutics Holdings, Inc. (RANI)
Automate Your Wheel Strategy on RANI
With Tiblio's Option Bot, you can configure your own wheel strategy including RANI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RANI
- Rev/Share 0.0328
- Book/Share -0.2505
- PB -3.4707
- Debt/Equity -3.4777
- CurrentRatio 0.5369
- ROIC -3.9534
- MktCap 38649688.0
- FreeCF/Share -0.8553
- PFCF -1.2366
- PE -0.6518
- Debt/Assets 1.1474
- DivYield 0
- ROE 33.7437
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
Read More
Rani Therapeutics Announces Research Agreement with Chugai
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd.
Read More
About Rani Therapeutics Holdings, Inc. (RANI)
- IPO Date 2021-07-30
- Website https://www.ranitherapeutics.com
- Industry Biotechnology
- CEO Talat Imran
- Employees 105